Patents by Inventor Hye-Jin Son
Hye-Jin Son has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240144512Abstract: Disclosed are an apparatus and method for measuring a dimension. The method of measuring a dimension according to an aspect of the present invention includes photographing a target object and generating an image, normalizing the image of the target object, generating normalized estimated dimension information about the target object from the normalized image of the target object using a pre-trained dimension prediction model, and converting the normalized estimated dimension information of the target object into estimated dimension information of the target object.Type: ApplicationFiled: October 26, 2023Publication date: May 2, 2024Inventors: Hye Jin S. KIM, Ji Yeon SON
-
Publication number: 20240120287Abstract: Provided is an overlay mark. The overlay mark comprises a substrate, a lower overlay in the substrate, a pattern layer on the substrate, and an upper overlay defining an opening on the pattern layer. The lower overlay does not overlap the upper overlay in a thickness direction of the substrate.Type: ApplicationFiled: October 3, 2023Publication date: April 11, 2024Applicant: Samsung Electronics Co., Ltd.Inventors: Sang Won PARK, A Yeong CHA, Byeong-Hwan SON, Hye Jin LEE, Jung Hyun CHOI, Jong Hee HAN
-
Publication number: 20230202992Abstract: The present invention relates to a pharmaceutical composition for preventing or treating small cell lung cancer associated with a RON mutation and a method using the same. The compound according to the present invention may be usefully used as a precision medicine in the treatment of a patient with small cell lung cancer which has resistance to an EGFR-targeted therapeutic agent used in conventional anticancer therapy and has the RON?155, RON?160, and RON?165 mutations.Type: ApplicationFiled: May 18, 2021Publication date: June 29, 2023Inventors: Hye-Jin SON, Mi-So LEE, Hyo-Jin KIM, Moon-Seong YOO, Jun-Hyung LEE, Yu-Geun JI
-
Patent number: 10716771Abstract: The present invention relates to a biguanide derivative compound capable of effectively preventing and treating immune diseases. The biguanide-based derivative compound according to the present invention inhibits the generation of IL-17 and TNF-?, which are inflammatory cytokines, increases the activity of regulatory T cells having an immunomodulatory function, and exhibits excellent therapeutic effects in animal models of immune diseases. Accordingly, the biguanide-based derivative compound can be usefully used as an immunosuppressant or a pharmaceutical composition capable of preventing or treating various immune diseases, such as autoimmune diseases, inflammatory diseases, and transplant rejection, caused by the dysregulation of immune responses.Type: GrantFiled: June 19, 2019Date of Patent: July 21, 2020Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC CORPORATION FOUNDATIONInventors: Mi-La Cho, Chul-Woo Yang, Dong-Yun Shin, Min-Jung Park, Seon-Yeong Lee, Sung-Hee Lee, Eun-Ji Yang, Hye-Jin Son, Eun-Kyung Kim, Jae-Kyung Kim
-
Publication number: 20190328685Abstract: The present invention relates to a biguanide derivative compound capable of effectively preventing and treating immune diseases. The biguanide-based derivative compound according to the present invention inhibits the generation of IL-17 and TNF-?, which are inflammatory cytokines, increases the activity of regulatory T cells having an immunomodulatory function, and exhibits excellent therapeutic effects in animal models of immune diseases. Accordingly, the biguanide-based derivative compound can be usefully used as an immunosuppressant or a pharmaceutical composition capable of preventing or treating various immune diseases, such as autoimmune diseases, inflammatory diseases, and transplant rejection, caused by the dysregulation of immune responses.Type: ApplicationFiled: June 19, 2019Publication date: October 31, 2019Applicant: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Mi-La Cho, Chul-Woo Yang, Dong-Yun Shin, Min-Jung Park, Seon-Yeong Lee, Sung-Hee Lee, Eun-Ji Yang, Hye-Jin Son, Eun-Kyung Kim, Jae-Kyung Kim
-
Patent number: 10369121Abstract: The present invention relates to a biguanide derivative compound capable of effectively preventing and treating immune diseases. The biguanide-based derivative compound according to the present invention inhibits the generation of IL-17 and TNF-?, which are inflammatory cytokines, increases the activity of regulatory T cells having an immunomodulatory function, and exhibits excellent therapeutic effects in animal models of immune diseases. Accordingly, the biguanide-based derivative compound can be usefully used as an immunosuppressant or a pharmaceutical composition capable of preventing or treating various immune diseases, such as autoimmune diseases, inflammatory diseases, and transplant rejection, caused by the dysregulation of immune responses.Type: GrantFiled: August 25, 2014Date of Patent: August 6, 2019Assignee: The Catholic University of Korea Industry-Academic Cooperation FoundationInventors: Mi-La Cho, Chul-Woo Yang, Dong-Yun Shin, Min-Jung Park, Seon-Yeong Lee, Sung-Hee Lee, Eun-Ji Yang, Hye-Jin Son, Eun-Kyung Kim, Jae-Kyung Kim
-
Publication number: 20190228112Abstract: Provided is an apparatus for quality rating-based three-dimensional modeling of nuclear power plant equipment. The apparatus performs: receiving, from a design information database, design information of atomic power plant equipment and information on multiple components constituting the atomic power plant equipment; receiving, from a quality rating database, information on the quality rating of each of the multiple components; performing, according to the design information of the nuclear power plant equipment, three-dimensional modeling of at least some of the multiple components constituting the atomic power plant equipment; and displaying the at least some three-dimensionally modeled components among the multiple components, wherein the apparatus may further display information on the quality rating corresponding to each of the multiple components.Type: ApplicationFiled: September 22, 2016Publication date: July 25, 2019Inventors: Hye Jin SON, Byeong Suk MOON, Sang Hyun LEE
-
Patent number: 10100006Abstract: Provided is a novel compound capable of effectively preventing and treating immune diseases and a use thereof. The novel compound of the present subject matter has effects of inhibiting the production of inflammatory cytokines, increasing the activity of regulatory T cells having immunoregulatory functions, inhibiting the production of auto-antibodies to regulate excessive immune responses, and inhibiting the differentiation of osteoclasts, and thus can be used for treating immune diseases, such as autoimmune disease, inflammatory disease, and transplant rejection diseases, which are caused by abnormal regulation of various kinds of immune response.Type: GrantFiled: November 21, 2017Date of Patent: October 16, 2018Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Mi-La Cho, Dong-Yun Shin, Sung-Hwan Park, Chul-Woo Yang, Jong-Young Choi, Min-Jung Park, Hye-Jin Son, Sung-Hee Lee, Seon-Yeong Lee, Eun-Kyung Kim, Jae-Kyung Kim, Seung-Hun Lee, Seong-Hyeok Park
-
Publication number: 20180118668Abstract: The present invention relates to a novel compound capable of effectively preventing and treating immune diseases and a use thereof.Type: ApplicationFiled: November 21, 2017Publication date: May 3, 2018Applicant: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Mi-La CHO, Dong-Yun SHIN, Sung-Hwan PARK, Chul-Woo YANG, Jong-Young CHOI, Min-Jung PARK, Hye-Jin SON, Sung-Hee LEE, Seon-Yeong LEE, Eun-Kyung KIM, Jae-Kyung KIM, Seung-Hun LEE, Seong-Hyeok PARK
-
Publication number: 20170333370Abstract: The present invention relates to a biguanide derivative compound capable of effectively preventing and treating immune diseases. The biguanide-based derivative compound according to the present invention inhibits the generation of IL-17 and TNF-?, which are inflammatory cytokines, increases the activity of regulatory T cells having an immunomodulatory function, and exhibits excellent therapeutic effects in animal models of immune diseases. Accordingly, the biguanide-based derivative compound can be usefully used as an immunosuppressant or a pharmaceutical composition capable of preventing or treating various immune diseases, such as autoimmune diseases, inflammatory diseases, and transplant rejection, caused by the dysregulation of immune responses.Type: ApplicationFiled: August 25, 2014Publication date: November 23, 2017Applicant: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Mi-La CHO, Chul-Woo YANG, Dong-Yun SHIN, Min-Jung PARK, Seon-Yeong LEE, Sung-Hee LEE, Eun-Ji YANG, Hye-Jin SON, Eun-Kyung KIM, Jae-Kyung KIM
-
Patent number: 9700531Abstract: The present invention relates to a composition comprising metformin as an active ingredient for preventing or treating inflammatory bowel disease. The metformin compound or the metformin-etanercept (product name: Enbrel) composite according to the present invention may have excellent effects of maintaining the thickness of the small intestine and length of the large intestine normal, inhibiting or decreasing the activity of IL-17 and TNF-a, and promoting or increasing the activity of IFNr, and therefore can be effectively used as a pharmaceutical composition for preventing or treating autoimmune diseases including inflammatory bowel disease.Type: GrantFiled: March 19, 2015Date of Patent: July 11, 2017Assignee: Catholic University Industry Academic Cooperation FoundationInventors: Mi-La Cho, Seon-Yeong Lee, Eun-Ji Yang, Hye-Jin Son, Eun-Kyung Kim, Jun-Geol Ryu
-
Publication number: 20170157069Abstract: The present invention relates to a composition for preventing or treating immune diseases through the suppression of B cell activity induced by metformin. More particularly, the present invention relates to a composition comprising a metformin compound or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating immune diseases, wherein the composition is characterized by suppression or reduction of B cell activity which is a cause of disease. The present invention can be valuable in the use thereof for various autoimmune diseases as an immunosuppressant which can prevent or treat immune diseases by suppressing or reducing B cell activity and Th17 cell activity, which are causes of disease, or by promoting or increasing regulatory T cell activity.Type: ApplicationFiled: February 23, 2017Publication date: June 8, 2017Applicant: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATIONInventors: Mi-La CHO, Seon-Yeong LEE, Min-Jung PARK, Jae-Seon LEE, Eun-Ji YANG, Eun-Kyung KIM, Jun-Geol RYU, Hye-Jin SON
-
Publication number: 20170114008Abstract: The present invention relates to a novel compound capable of effectively preventing and treating immune diseases and a use thereof.Type: ApplicationFiled: October 31, 2016Publication date: April 27, 2017Inventors: Mi-La CHO, Dong-Yun SHIN, Sung-Hwan PARK, Chul-Woo YANG, Jong-Young CHOI, Min-Jung PARK, Hye-Jin SON, Sung-Hee LEE, Seon-Yeong LEE, Eun-Kyung KIM, Jae-Kyung KIM, Seung-Hun LEE, Seong-Hyeok PARK
-
Patent number: 9585945Abstract: The present invention relates to a composition for preventing or treating an autoimmune disease comprising, as an active ingredient, PINK1 protein or polynucleotide encoding the same. The PINK1 protein according to the present invention inhibits the activity of Th17, promotes the activity of a regulatory T cell (Treg), and increases autophagy in Treg cells, thereby controlling excessive immune responses. Therefore, the PINK1 protein can be effectively used as a pharmaceutical composition or an immunosuppressant, which is capable of preventing or treating an autoimmune disease, such as arthritis, and the like, caused by dysregulation of various kinds of immune responses.Type: GrantFiled: November 20, 2015Date of Patent: March 7, 2017Assignee: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATIONInventors: Mi-La Cho, Hyang-Suk Rhim, Seon-Yeong Lee, Yeong-Mi Mun, Hye-Jin Son, Eun-Ji Yang, Eun-Kyung Kim
-
Patent number: 9526717Abstract: The daurinol compound according to the present invention exhibits excellent therapeutic effects on arthritis and inflammatory bowel diseases by having an excellent activity in inhibiting the generation of IL-17 and TNF-?, which are inflammatory cytokines causing inflammation, and can alleviate transplant rejection by inhibiting the proliferation of alloreactive T cells and increasing regulatory T cells; therefore, the daurinol compound according to the present invention can be used as a pharmaceutical composition capable of treating and preventing immune diseases. In addition, being a natural substance derived from the Mongolian medicinal plant Haplophyllum dauricum or Haplophyllum cappadocicum, the daurinol compound according to the present invention does not cause cytotoxicity and thus may be used as a composition for a functional health food capable of preventing and remedying immune diseases.Type: GrantFiled: August 22, 2014Date of Patent: December 27, 2016Assignee: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CATHOLIC UNIV. OF KOREA SONGEUI CAMPUSInventors: Mi-La Cho, Dong-Yun Shin, Min-Jung Park, Seon-Yeong Lee, Eun Ji Yang, Eun Kyung Kim, Hye-Jin Son, Eun-Jung Lee, Jae-Kyung Kim, Sung-Hee Lee
-
Publication number: 20160193180Abstract: The daurinol compound according to the present invention exhibits excellent therapeutic effects on arthritis and inflammatory bowel diseases by having an excellent activity in inhibiting the generation of IL-17 and TNF-?, which are inflammatory cytokines causing inflammation, and can alleviate transplant rejection by inhibiting the proliferation of alloreactive T cells and increasing regulatory T cells; therefore, the daurinol compound according to the present invention can be used as a pharmaceutical composition capable of treating and preventing immune diseases. In addition, being a natural substance derived from the Mongolian medicinal plant Haplophyllum dauricum or Haplophyllum cappadocicum, the daurinol compound according to the present invention does not cause cytotoxicity and thus may be used as a composition for a functional health food capable of preventing and remedying immune diseases.Type: ApplicationFiled: August 22, 2014Publication date: July 7, 2016Applicant: The Catholic University of Korea Industry-Academic Cooperation FoundationInventors: Mi-La CHO, Dong-Yun SHIN, Min-Jung PARK, Seon-Yeong LEE, Eun Ji YANG, Eun Kyung KIM, Hye-Jin SON, Eun-Jung LEE, Jae-Kyung KIM, Sung-Hee LEE
-
Publication number: 20160114007Abstract: The present invention relates to a composition for preventing or treating an autoimmune disease comprising, as an active ingredient, PINK1 protein or polynucleotide encoding the same. The PINK1 protein according to the present invention inhibits the activity of Th17, promotes the activity of a regulatory T cell (Treg), and increases autophagy in Treg cells, thereby controlling excessive immune responses. Therefore, the PINK1 protein can be effectively used as a pharmaceutical composition or an immunosuppressant, which is capable of preventing or treating an autoimmune disease, such as arthritis, and the like, caused by dysregulation of various kinds of immune responses.Type: ApplicationFiled: November 20, 2015Publication date: April 28, 2016Inventors: Mi-La Cho, Hyang-Suk Rhim, Seon-Yeong Lee, Yeong-Mi Mun, Hye-Jin Son, Eun-Ji Yang, Eun-Kyung Kim
-
Publication number: 20150297676Abstract: The present invention relates to a composition comprising GRIM-19 protein as an active ingredient for preventing or treating obesity or lipid-related metabolic diseases. More particularly, the present invention relates to a composition for preventing or treating obesity or lipid-related metabolic diseases wherein the composition comprises GRIM-19 protein as an active ingredient for preventing or treating metabolic diseases caused by immune response disorders or interactions between genetic, metabolic, or environmental complex factors. The GRIM-19 protein according to the present invention exhibits excellent effectiveness not only in reducing lipocytes and total cholesterol content in the body, but also in suppressing the differentiation of cytotoxic Th17 cells that produce and secrete inflammatory cytokines. Also, GRIM-19 has been found to have excellent effectiveness in regulating a STAT3 mediated inflammatory response in an inflammatory environment related to obesity.Type: ApplicationFiled: September 2, 2013Publication date: October 22, 2015Applicant: Catholic University Industry Academic Cooperation FoundationInventors: Mi-La CHO, Joo-Yeon Jhun, Seon-Yeong Lee, Yeong-Mi Mun, Jun-Geol Ryu, Jae-Kyeong Byun, Hye-Jin Son, Eun-Kyung Kim, Eun-Ji Yang, Jeong-Hee Jeong
-
Publication number: 20150238445Abstract: The present invention relates to a composition for preventing or treating immune diseases through the suppression of B cell activity induced by metformin. More particularly, the present invention relates to a composition comprising a metformin compound or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating immune diseases, wherein the composition is characterized by suppression or reduction of B cell activity which is a cause of disease. The present invention can be valuable in the use thereof for various autoimmune diseases as an immunosuppressant which can prevent or treat immune diseases by suppressing or reducing B cell activity and Th17 cell activity, which are causes of disease, or by promoting or increasing regulatory T cell activity.Type: ApplicationFiled: September 6, 2013Publication date: August 27, 2015Inventors: Mi-La Cho, Seon-Yeong Lee, Min-Jung Park, Jae-Seon Lee, Eun-Ji Yang, Eun-Kyung Kim, Jun-Geol Ryu, Hye-Jin Son
-
Publication number: 20150196511Abstract: The present invention relates to a composition comprising metformin as an active ingredient for preventing or treating inflammatory bowel disease. The metformin compound or the metformin-etanercept (product name: Enbrel) composite according to the present invention may have excellent effects of maintaining the thickness of the small intestine and length of the large intestine normal, inhibiting or decreasing the activity of IL-17 and TNF-a, and promoting or increasing the activity of IFNr, and therefore can be effectively used as a pharmaceutical composition for preventing or treating autoimmune diseases including inflammatory bowel disease.Type: ApplicationFiled: March 19, 2015Publication date: July 16, 2015Inventors: Mi-La Cho, Seon-Yeong Lee, Eun-Ji Yang, Hye-Jin Son, Eun-Kyung Kim, Jun-Geol Ryu